Drawing based on the label description. No photo yet.
“60 mg, white to off-white, capsule-shaped, film-coated tablets (not scored), debossed with "7290" on one side of the tablet, and "93" on the other”
7290 93 pill
Pill with imprint 7290 93 is white, capsule, 12 mm and has been identified as Raloxifene Hydrochloride 60 mg. It is used for osteoporosis (weak bones). It is supplied by Aphena Pharma Solutions - Tennessee, LLC.
Raloxifene Hydrochloride 60 mg
- Imprint
- 7290 93
- Strength
- 60 mg
- Used for
- Osteoporosis (weak bones)
- Color
- White
- Shape
- Capsule / oblong
- Size
- 12 mm
- Score
- No score line
- Form
- Tablet, film coated
- Manufacturer
- Aphena Pharma Solutions - Tennessee, LLC
- Drug class
- Estrogen modulator
- NDC
- 71610-504, 0093-7290, 71610-504-60, 68071-2412, 68071-2412-3, 0093-7290-56, 0093-7290-01, 71335-1715, 71335-1715-1, 71335-1715-2
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
What is Raloxifene used for?
Raloxifene is used for osteoporosis (weak bones).
- Medicine type
- Estrogen modulator
Official uses from the US prescribing label
Treatment and Prevention of Osteoporosis in Postmenopausal Women
EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women.
Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis
EVISTA is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis.
Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women at High Risk of Invasive Breast Cancer
EVISTA is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.
The effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years. Twenty-seven percent of the participants received drug for 5 years. The long-term effects and the recommended length of treatment are not known.
High risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (LCIS) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer ≥1.66% (based on the modified Gail model). Among the factors included in the modified Gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. Healthcare professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-800-545-5979. Currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.
After an assessment of the risk of developing breast cancer, the decision regarding therapy with EVISTA should be based upon an individual assessment of the benefits and risks.
EVISTA does not eliminate the risk of breast cancer. Patients should have breast exams and mammograms before starting EVISTA and should continue regular breast exams and mammograms in keeping with good medical practice after beginning treatment with EVISTA.
Important Limitations of Use for Breast Cancer Risk Reduction
- There are no data available regarding the effect of EVISTA on invasive breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of EVISTA.
- EVISTA is not indicated for the treatment of invasive breast cancer or reduction of the risk of recurrence.
- EVISTA is not indicated for the reduction in the risk of noninvasive breast cancer.
From the FDA-approved label on DailyMed (published Sep 02, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- One side shows 7290 and the other side shows 93.
- It is white, capsule, 12 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Ingredients
Active: Raloxifene Hydrochloride
Inactive: Silicon Dioxide, Hypromellose 2910 (15 Mpa.s), Magnesium Stearate, Cellulose, Microcrystalline, Polydextrose, Polyethylene Glycol 4000, Povidone K30, Starch, Corn, Titanium Dioxide
Also distributed by
Nucare Pharmaceuticals,inc., Teva Pharmaceuticals Usa, Inc., Bryant Ranch Prepack
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
AA 77
Ethacrynic Acid 25 mg
White, capsule, 11 mm
Used for high blood pressure and heart failure
-
F 41
Atomoxetine 10 mg
White, capsule, 11 mm
Used for ADHD
-
G 200
Telmisartan 40 mg
White, capsule, 12 mm
Used for high blood pressure and heart failure
-
AN 26
Lisdexamfetamine 50 mg
Blue & white, capsule, 11 mm
Used for ADHD and binge drinking
Schedule II
-
AN 25
Lisdexamfetamine 40 mg
Green & white, capsule, 11 mm
Used for ADHD and binge drinking
Schedule II
-
AN 24
Lisdexamfetamine 30 mg
Orange & white, capsule, 11 mm
Used for ADHD and binge drinking
Schedule II
Other Raloxifene pills
-
IG 256
Raloxifene 60 mg
White, round, 9 mm
Used for osteoporosis (weak bones)
-
AN057
Raloxifene Hydrochloride 60 mg
White, oval, 12 mm
Used for osteoporosis (weak bones)
- LLILY 4165 Raloxifene Hydrochloride 60 mg White, oval, 12 mm Used for osteoporosis (weak bones)
- IG 256 Raloxifene Hydrochloride 60 mg White, round, 9 mm Used for osteoporosis (weak bones)
- SG 306 Raloxifene Hydrochloride 60 mg White, oval, 12 mm Used for osteoporosis (weak bones)
- C79 Raloxifene Hydrochloride 60 mg White, oval, 12 mm Used for osteoporosis (weak bones)
- X 57 Raloxifene Hydrochloride 60 mg White, oval, 12 mm Used for osteoporosis (weak bones)
- 393 Raloxifene Hydrochloride 60 mg White, oval, 12 mm Used for osteoporosis (weak bones)